Plus therapeutics, inc. (CYTX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Product revenues

-

-

-

-

-

-

-

-

731

-

467

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

581

0

Third party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,076

2,134

2,411

1,362

938

2,091

Product revenues

-

-

-

-

-

-

-

-

-

-

-

969

591

1,466

731

1,126

1,333

1,556

766

1,614

902

2,469

518

935

1,031

2,706

1,616

1,408

1,392

3,967

1,314

1,947

1,481

-

-

-

-

1,519

2,091

Cost of product revenues

-

-

-

-

-

-

-

-

273

-

181

401

410

638

561

503

468

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

306

-

306

306

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross profit

-

-

-

-

-

-

-

-

152

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

306

307

57

82

99

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

790

502

1,296

598

1,416

337

766

421

1,126

931

608

756

1,412

703

1,032

853

944

942

1,109

842

920

883

Gross profit (loss)

-

-

-

-

-

-

-

-

-

-

-20

262

-125

521

113

541

766

766

264

318

304

1,053

181

169

610

1,580

685

800

636

2,555

611

915

628

1,132

1,192

1,302

520

599

1,208

Development revenues:
Development, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

638

469

0

2,413

0

761

0

0

1,231

0

0

Development revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,179

-

0

0

0

-

-

-

-

-

-

Government contracts and other

118

1,188

4,771

302

737

713

454

899

917

867

1,306

531

1,018

1,561

1,879

1,699

1,585

1,819

1,711

1,847

1,444

1,301

585

356

403

754

1,095

859

549

360

2

16

3

-

-

-

-

-

-

Total development revenues

-

-

4,771

302

-

713

454

899

917

867

1,306

531

1,018

1,561

1,879

1,699

1,585

-

1,711

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research grant and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

11

4

65

7

Total development revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,847

-

-

-

-

-

754

1,095

859

2,366

3,358

2

2,429

3

762

5

11

1,235

65

7

Operating expenses:
Research and development

941

1,729

921

1,289

1,426

531

1,226

1,267

2,499

2,393

3,004

2,992

3,289

2,863

3,960

5,247

4,127

4,637

4,352

6,048

3,963

2,999

3,140

4,674

4,292

5,072

4,123

4,150

3,720

4,013

3,555

3,224

2,836

1,956

2,830

3,071

3,047

2,480

2,301

Sales and marketing

110

163

94

97

114

-338

118

185

678

551

840

1,263

939

869

818

889

1,035

603

566

654

839

1,073

1,471

1,934

1,928

2,573

1,786

2,410

2,257

2,081

2,450

2,581

2,376

3,000

3,618

3,716

3,226

2,932

2,425

General and administrative

1,508

1,508

1,076

875

1,363

705

1,337

1,293

2,244

1,582

1,785

2,119

2,108

1,938

2,011

2,328

2,286

2,103

2,370

2,793

2,499

2,832

4,179

4,602

4,340

3,807

4,332

4,046

3,846

4,183

3,777

3,788

3,924

3,498

3,538

4,147

3,544

3,060

3,052

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

84

334

-

-863

-251

-130

-

-1,536

-5,649

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,471

1,803

-1,461

Change in fair value of option liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,500

-250

150

-300

-460

270

-1,420

570

400

-290

-20

-60

Total operating expenses

2,559

3,400

2,091

2,261

2,903

898

2,681

2,745

5,421

4,526

5,629

6,374

8,022

5,670

6,789

8,464

7,448

4,663

-22

-3,627

22,745

6,669

8,656

11,210

10,560

11,452

10,241

8,022

9,739

8,674

10,945

10,304

8,996

7,868

9,020

5,685

12,998

10,255

6,257

Operating loss

-2,441

-2,212

2,680

-1,959

-2,166

-337

-2,227

-1,846

-4,352

-3,630

-4,343

-5,581

-7,129

-3,588

-4,797

-6,224

-5,097

-2,078

1,997

5,792

-20,997

-4,315

-7,890

-10,685

-9,547

-9,118

-8,461

-6,363

-6,737

-2,761

-10,332

-6,960

-8,365

-5,974

-7,823

-4,372

-11,243

-9,591

-5,042

Other income (expense):
Income (loss) on asset disposal

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-1

-

-

-14

-1

-

-

0

-257

-

-

0

0

-

-

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-260

-

-

0

0

-

-

0

-708

-

-

0

0

-

-

-

-

-

-

-

Interest income

36

35

6

7

7

13

11

5

14

10

5

7

11

11

4

2

2

2

3

3

1

2

1

1

2

2

1

1

0

1

0

1

2

3

3

1

2

3

2

Interest expense

349

377

366

597

515

542

513

444

423

446

474

538

591

645

645

645

657

702

669

936

1,072

1,085

1,260

1,085

941

941

1,094

652

709

804

857

860

865

861

489

696

738

759

254

Other income (expense), net

-

-

-

-

-

-

-

-

352

-220

5

63

165

-696

54

462

413

11

199

-148

110

-414

-222

-58

86

-45

-96

-124

-173

-223

-17

-27

-47

-18

25

-15

-47

-27

-49

Change in fair value of warrants

-1,667

-3,476

561

-282

-210

-557

-1,676

0

0

-

-

-

-

-

-

-

-

-2,680

-7,310

-13,122

15,444

-235

-134

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance cost of warrants

-

-

1,233

-

-

-

343

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Puregraft divestiture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,392

-

-

-

-

-

-

-

-

-

-

-

-

Gain on previously held equity interest in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4,892

-

-

0

0

-

-

-

-

-

-

-

Equity loss from investment in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-48

-36

-42

-37

-50

-56

-51

-56

-46

-43

-34

Total other income (expense)

1,354

3,134

-2,154

-308

-298

-451

831

-439

-57

-656

-464

-468

-415

-1,330

-587

-181

-242

-685

-470

-1,342

-961

-1,440

-1,495

-1,143

-853

-923

3,203

3,152

-930

-1,062

-916

-923

-960

-932

-512

-766

-829

-826

-335

Loss from continuing operations

-1,087

922

526

-2,267

-2,464

-

-1,396

-2,285

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-36

-2

-6,880

-686

-

-934

-1,374

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-1,087

884

526

-9,147

-3,150

-2,236

-2,330

-3,659

-4,409

-4,286

-4,807

-6,049

-7,544

-4,918

-5,384

-6,405

-5,339

-2,763

1,527

4,450

-21,958

-5,755

-9,385

-11,828

-10,400

-10,041

-5,258

-3,211

-7,667

-3,823

-11,248

-7,883

-9,325

-6,906

-8,335

-5,138

-12,072

-10,417

-5,377

Income (Loss) from continuing operations

-1,087

-

526

-

-2,464

-

-1,396

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Beneficial conversion feature for convertible preferred stock

-

-

554

-

-

-

2,487

-

-

-

-

-

-

-

-

-

-

0

1,322

-1,322

661

1,169

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders - continuing operations

-

-

-28

-

-

-

-3,883

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders - discontinued operations

-

-

-

-

-

-

-934

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-

-

-

-4,807

-

-

-

-

-

-

-2,763

1,527

4,450

-22,619

-6,924

-9,385

-11,828

-10,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share attributable to common stockholders - continuing operations

-0.28

9.36

-0.03

-5.12

-6.98

-

-22.27

-18.53

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share attributable to common stockholders - discontinued operations

-

8.48

3.52

-15.55

-1.94

-

-5.36

-11.14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basis and diluted

-0.28

21.35

-0.03

-20.67

-8.92

-28.95

-27.63

-29.67

-0.73

-4.57

-1.39

-1.94

-0.33

-0.18

-0.26

-0.43

-0.41

-

-

-

-3.19

-

-

-

-0.14

-0.15

-0.08

-0.05

-0.11

-0.07

-0.19

-0.13

-0.16

-

-0.15

-0.10

-

-

-

Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders

3,880

3,913

826

442

353

-5,620

174

123

6,017

-16,354

3,449

3,125

22,736

20,804

20,493

14,778

13,086

-

-

-

7,080

-

-

-

74,102

69,685

67,248

67,200

66,990

59,844

58,713

58,676

57,484

-

53,900

52,411

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.15

0.48

-

-

-0.12

-0.15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.15

0.45

-

-

-0.12

-0.15

-

-

-

-

-

-

-

-

-

-

-

-

-0.23

-0.23

-0.12

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,253

9,266

-

-

80,430

76,682

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,531

9,824

-

-

80,430

76,682

-

-

-

-

-

-

-

-

-

-

-

-

51,994

45,905

45,295

Comprehensive loss:
Net loss

-1,087

884

526

-9,147

-3,150

-2,236

-2,330

-3,659

-4,409

-4,286

-4,807

-6,049

-7,544

-4,918

-5,384

-6,405

-5,339

-2,763

1,527

4,450

-21,958

-5,755

-9,385

-11,828

-10,400

-10,041

-5,258

-3,211

-7,667

-3,823

-11,248

-7,883

-9,325

-6,906

-8,335

-5,138

-12,072

-10,417

-5,377

Other comprehensive loss – foreign currency translation adjustments

-

-

-

-

-140

36

-55

131

-281

188

16

-15

-60

583

58

-130

-249

-65

110

215

36

243

58

193

-50

398

-108

76

-110

0

0

0

0

-

-

-

-

-

-

Comprehensive loss

-1,087

1,024

526

-9,147

-3,290

-2,200

-2,385

-3,528

-4,690

-4,098

-4,791

-6,064

-7,604

-4,335

-5,326

-6,535

-5,588

-2,828

1,637

4,665

-21,922

-5,512

-9,327

-11,635

-10,450

-9,643

-5,366

-3,135

-7,777

-3,823

-11,248

-7,883

-9,325

-

-

-

-

-

-